[1]
|
Gilbert, J.A., et al. (2018) Current Understanding of the Human Microbiome. Nature Medicine, 24, 392-400.
https://doi.org/10.1038/nm.4517
|
[2]
|
Sender, R., Fuchs, S. and Milo, R. (2016) Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biology, 14, e1002533. https://doi.org/10.1371/journal.pbio.1002533
|
[3]
|
Cryan, J.F., et al. (2019) The Microbiota-Gut-Brain Axis. Phys-iological Reviews, 99, 1877-2013.
https://doi.org/10.1152/physrev.00018.2018
|
[4]
|
Codagnone, M.G., et al. (2019) Programming Bugs: Microbiota and the Developmental Origins of Brain Health and Disease. Biological Psychiatry, 85, 150-163. https://doi.org/10.1016/j.biopsych.2018.06.014
|
[5]
|
Claesson, M.J., et al. (2012) Gut Microbiota Composition Correlates with Diet and Health in the Elderly. Nature, 488, 178-184. https://doi.org/10.1038/nature11319
|
[6]
|
Sandhu, K.V., et al. (2017) Feeding the Microbiota-Gut-Brain Axis: Diet, Microbiome, and Neuropsychiatry. Translational Research, 179, 223-244. https://doi.org/10.1016/j.trsl.2016.10.002
|
[7]
|
Hugon, P., et al. (2015) A Comprehensive Repertoire of Prokaryotic Species Identified in Human Beings. The Lancet Infectious Diseases, 15, 1211-1219. https://doi.org/10.1016/S1473-3099(15)00293-5
|
[8]
|
Li, J. and Jia, H. (2014) An Integrated Catalog of Reference Genes in the Human Gut Microbiome. Nature Biotechnology, 32, 834-841.
|
[9]
|
Leitão-Gonçalves, R., et al. (2017) Commensal Bacteria and Essential Amino Acids Control Food Choice Behavior and Reproduction. PLOS Biology, 15, e2000862. https://doi.org/10.1371/journal.pbio.2000862
|
[10]
|
Nakazato, M., et al. (2001) A Role for Ghrelin in the Central Regulation of Feeding. Nature, 409, 194-198.
https://doi.org/10.1038/35051587
|
[11]
|
Wren, A.M., et al. (2001) Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes, 50, 2540-2547.
https://doi.org/10.2337/diabetes.50.11.2540
|
[12]
|
Shah, M. and Vella, A. (2014) Effects of GLP-1 on Appetite and Weight. Reviews in Endocrine and Metabolic Disorders, 15, 181-187. https://doi.org/10.1007/s11154-014-9289-5
|
[13]
|
Karra, E., Chandarana, K. and Batterham, R.L. (2009) The Role of Peptide YY in Appetite Regulation and Obesity. The Journal of Physiology, 587, 19-25. https://doi.org/10.1113/jphysiol.2008.164269
|
[14]
|
Tolhurst, G., et al. (2012) Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein- Coupled Receptor FFAR2. Diabetes, 61, 364-371. https://doi.org/10.2337/db11-1019
|
[15]
|
Cani, P.D., et al. (2009) Gut Microbiota Fermentation of Prebiotics In-creases Satietogenic and Incretin Gut Peptide Production with Consequences for Appetite Sensation and Glucose Re-sponse after a Meal. The American Journal of Clinical Nutrition, 90, 1236-1243. https://doi.org/10.3945/ajcn.2009.28095
|
[16]
|
Parnell, J.A. and Reimer, R.A. (2009) Weight Loss during Oli-gofructose Supplementation Is Associated with Decreased Ghrelin and Increased Peptide YY in Overweight and Obese Adults. The American Journal of Clinical Nutrition, 89, 1751-1759. https://doi.org/10.3945/ajcn.2009.27465
|
[17]
|
Lin, H.V., et al. (2012) Butyrate and Propionate Protect against Di-et-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. PLOS ONE, 7, e35240.
https://doi.org/10.1371/journal.pone.0035240
|
[18]
|
Xiong, Y., et al. (2004) Short-Chain Fatty Acids Stimulate Lep-tin Production in Adipocytes through the G Protein- Coupled Receptor GPR41. Proceedings of the National Academy of Sciences of the United States of America, 101, 1045- 1050. https://doi.org/10.1073/pnas.2637002100
|
[19]
|
Turnbaugh, P.J., et al. (2006) An Obesity-Associated Gut Micro-biome with Increased Capacity for Energy Harvest. Nature, 444, 1027-1031. https://doi.org/10.1038/nature05414
|
[20]
|
Tims, S., et al. (2013) Microbiota Conservation and BMI Signatures in Adult Monozygotic Twins. The ISME Journal, 7, 707-717. https://doi.org/10.1038/ismej.2012.146
|
[21]
|
Gophna, U., Konikoff, T. and Nielsen, H.B. (2017) Oscillospira and Related Bacteria—From Metagenomic Species to Metabolic Features. Environmental Microbiology, 19, 835-841. https://doi.org/10.1111/1462-2920.13658
|
[22]
|
Miller, T.L., et al. (1982) Isolation of Methanobrevibacter smithii from Human Feces. Applied and Environmental Microbiology, 43, 227-232. https://doi.org/10.1128/aem.43.1.227-232.1982
|
[23]
|
Ridaura, V.K., et al. (2013) Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. Science, 341, Article ID: 1241214. https://doi.org/10.1126/science.1241214
|
[24]
|
Petersen, C., et al. (2019) T Cell-Mediated Regulation of the Micro-biota Protects against Obesity. Science, 365, eaat9351. https://doi.org/10.1126/science.aat9351
|
[25]
|
Wu, Y., et al. (2019) The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-Brain Axis. Current Protein & Peptide Science, 20, 750-758. https://doi.org/10.2174/1389203720666190125105401
|
[26]
|
Bäckhed, F., et al. (2004) The Gut Microbiota as an Environmental Factor That Regulates Fat Storage. Proceedings of the National Academy of Sciences of the United States of America, 101, 15718-15723.
https://doi.org/10.1073/pnas.0407076101
|
[27]
|
Zhong, H., et al. (2019) Distinct Gut Metagenomics and Metapro-teomics Signatures in Prediabetics and Treatment- Naïve Type 2 Diabetics. EBioMedicine, 47, 373-383. https://doi.org/10.1016/j.ebiom.2019.08.048
|
[28]
|
Allin, K.H., et al. (2018) Aberrant Intestinal Microbiota in Indi-viduals with Prediabetes. Diabetologia, 61, 810-820.
https://doi.org/10.1007/s00125-018-4550-1
|
[29]
|
Wang, T.J., et al. (2011) Metabolite Profiles and the Risk of De-veloping Diabetes. Nature Medicine, 17, 448-453.
https://doi.org/10.1038/nm.2307
|
[30]
|
Koh, A., et al. (2018) Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell, 175, 947-961.e17. https://doi.org/10.1016/j.cell.2018.09.055
|
[31]
|
Vieira-Silva, S., et al. (2020) Statin Therapy Is Associated with Lower Prevalence of Gut Microbiota Dysbiosis. Nature, 581, 310-315. https://doi.org/10.1038/s41586-020-2269-x
|
[32]
|
Forslund, K., et al. (2015) Disentangling Type 2 Diabetes and Metformin Treatment Signatures in the Human Gut Microbiota. Nature, 528, 262-266. https://doi.org/10.1038/nature15766
|
[33]
|
Wu, H., et al. (2017) Metformin Alters the Gut Microbiome of Individu-als with Treatment-Naive Type 2 Diabetes, Contributing to the Therapeutic Effects of the Drug. Nature Medicine, 23, 850-858. https://doi.org/10.1038/nm.4345
|
[34]
|
Bryrup, T., et al. (2019) Metformin-Induced Changes of the Gut Microbiota in Healthy Young Men: Results of a Non- Blinded, One-Armed intervention Study. Diabetologia, 62, 1024-1035. https://doi.org/10.1007/s00125-019-4848-7
|
[35]
|
Cammarota, G., et al. (2015) Randomised Clinical Trial: Faecal Microbiota Transplantation by Colonoscopy vs. Vancomycin for the Treatment of Recurrent Clostridium difficile Infection. Alimentary Pharmacology & Therapeutics, 41, 835-843. https://doi.org/10.1111/apt.13144
|
[36]
|
van Nood, E., et al. (2013) Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. The New England Journal of Medicine, 368, 407-415. https://doi.org/10.1056/NEJMoa1205037
|
[37]
|
Hvas, C.L., et al. (2019) Fecal Microbiota Transplantation Is Supe-rior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology, 156, 1324-1332.e3. https://doi.org/10.1053/j.gastro.2018.12.019
|
[38]
|
Yu, E.W., et al. (2020) Fecal Microbiota Transplantation for the Improvement of Metabolism in Obesity: The FMT-TRIM Double-Blind Placebo-Controlled Pilot Trial. PLOS Medicine, 17, e1003051.
https://doi.org/10.1371/journal.pmed.1003051
|
[39]
|
Vermeire, S., et al. (2016) Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 10, 387-394. https://doi.org/10.1093/ecco-jcc/jjv203
|
[40]
|
Nicco, C., et al. (2020) From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. Diseases, 8, Article No. 9. https://doi.org/10.3390/diseases8020009
|
[41]
|
Paramsothy, S., et al. (2015) Donor Recruitment for Fecal Microbio-ta Transplantation. Inflammatory Bowel Diseases, 21, 1600-1606. https://doi.org/10.1097/MIB.0000000000000405
|
[42]
|
Costello, S.P., et al. (2015) Faecal Microbiota Transplant for Recurrent Clostridium difficile Infection Using Long- Term Frozen Stool Is Effective: Clinical Efficacy and Bacterial Via-bility Data. Alimentary Pharmacology & Therapeutics, 42, 1011-1018. https://doi.org/10.1111/apt.13366
|
[43]
|
Youngster, I., et al. (2014) Fecal Microbiota Transplant for Relapsing Clos-tridium difficile Infection Using a Frozen Inoculum from Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study. Clinical Infectious Diseases, 58, 1515-1522. https://doi.org/10.1093/cid/ciu135
|
[44]
|
Cammarota, G., Ianiro, G. and Gasbarrini, A. (2014) Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. Journal of Clinical Gastroenterology, 48, 693-702.
https://doi.org/10.1097/MCG.0000000000000046
|
[45]
|
Postigo, R. and Kim, J.H. (2012) Colonoscopic versus Nasogastric Fecal Transplantation for the Treatment of Clostridium difficile Infection: A Review and Pooled Analysis. Infection, 40, 643-648.
https://doi.org/10.1007/s15010-012-0307-9
|
[46]
|
Cammarota, G., et al. (2015) Decrease in Surgery for Clostridium difficile Infection after Starting a Program to Transplant Fecal Microbiota. Annals of Internal Medicine, 163, 487-488. https://doi.org/10.7326/L15-5139
|
[47]
|
Vindigni, S.M. and Surawicz, C.M. (2017) Fecal Microbiota Transplanta-tion. Gastroenterology Clinics of North America, 46, 171-185. https://doi.org/10.1016/j.gtc.2016.09.012
|
[48]
|
Cammarota, G., et al. (2019) International Consensus Conference on Stool Banking for Faecal Microbiota Transplantation in Clinical Practice. Gut, 68, 2111-2121. https://doi.org/10.1136/gutjnl-2019-319548
|
[49]
|
Goldenberg, S.D., et al. (2018) Comparison of Different Strate-gies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infectious Diseases and Therapy, 7, 71-86. https://doi.org/10.1007/s40121-018-0189-y
|
[50]
|
DeFilipp, Z., et al. (2019) Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. The New England Journal of Medicine, 381, 2043-2050. https://doi.org/10.1056/NEJMoa1910437
|
[51]
|
Vrieze, A., et al. (2012) Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome. Gastroenterology, 143, 913-916.e7. https://doi.org/10.1053/j.gastro.2012.06.031
|
[52]
|
Kootte, R.S., et al. (2017) Improvement of Insulin Sensitivity af-ter Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 26, 611-619.e6.
|
[53]
|
Ng, S.C. and Xu, Z. (2021) Microbiota Engraftment after Faecal Microbiota Transplantation in Obese Subjects with Type 2 Diabetes: A 24-Week, Double-Blind, Randomised Controlled Trial. Gut, 71, 716-723.
https://doi.org/10.1136/gutjnl-2020-323617
|
[54]
|
Rinott, E., et al. (2021) Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology, 160, 158-173.e10. https://doi.org/10.1053/j.gastro.2020.08.041
|
[55]
|
de Groot, P., et al. (2021) Faecal Microbiota Transplantation Halts Progression of Human New-Onset Type 1 Diabetes in a Randomised Controlled Trial. Gut, 70, 92-105. https://doi.org/10.1136/gutjnl-2020-322630
|
[56]
|
Witjes, J.J., et al. (2020) Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals with Steatohepatitis. Hepatology Communications, 4, 1578-1590. https://doi.org/10.1002/hep4.1601
|
[57]
|
Abt, M.C., et al. (2012) Commensal Bacteria Calibrate the Ac-tivation Threshold of Innate Antiviral Immunity. Immunity, 37, 158-170. https://doi.org/10.1016/j.immuni.2012.04.011
|
[58]
|
Rosser, E.C., et al. (2014) Regulatory B Cells Are Induced by Gut Microbiota-Driven Interleukin-1β and Interleukin-6 Production. Nature Medicine, 20, 1334-1339. https://doi.org/10.1038/nm.3680
|
[59]
|
Tailford, L.E., et al. (2015) Mucin Glycan Foraging in the Human Gut Mi-crobiome. Frontiers in Genetics, 6, Article No. 81. https://doi.org/10.3389/fgene.2015.00081
|
[60]
|
Hotamisligil, G.S., Inflammation and Metabolic Disorders. Nature, 444, 860-867. https://doi.org/10.1038/nature05485
|
[61]
|
Cani, P.D., et al. (2007) Selective Increases of Bifidobacteria in Gut Microflora Improve High-Fat-Diet-Induced Diabetes in Mice through a Mechanism Associated with Endotoxaemia. Diabetologia, 50, 2374-2383.
https://doi.org/10.1007/s00125-007-0791-0
|
[62]
|
Wexler, A.G. and Goodman, A.L. (2017) An Insider’s Perspec-tive: Bacteroides as a Window into the Microbiome. Nature Microbiology, 2, Article No. 17026. https://doi.org/10.1038/nmicrobiol.2017.26
|
[63]
|
Ramakrishna, C., et al. (2019) Bacteroides Fragilis Polysaccharide A Induces IL-10 Secreting B and T Cells That Prevent Viral Encephalitis. Nature Communications, 10, Article No. 2153. https://doi.org/10.1038/s41467-019-09884-6
|
[64]
|
Mishima, Y., et al. (2019) Microbiota Maintain Colonic Homeo-stasis by Activating TLR2/MyD88/PI3K Signaling in IL-10-Producing Regulatory B Cells. Journal of Clinical Investiga-tion, 129, 3702-3716.
https://doi.org/10.1172/JCI93820
|
[65]
|
Mishima, Y., et al. (2015) Resident Bacteria-Stimulated IL-10-Secreting B Cells Ameliorate T Cell-Mediated Colitis by Inducing Tr-1 Cells That Require IL-27-Signaling. Cellular and Molecular Gastroenterology and Hepatology, 1, 295-310. https://doi.org/10.1016/j.jcmgh.2015.01.002
|
[66]
|
Round, J.L. and Mazmanian, S.K. (2009) The Gut Microbiota Shapes Intestinal Immune Responses during Health and Disease. Nature Reviews Immunology, 9, 313-323. https://doi.org/10.1038/nri2515
|
[67]
|
Vinolo, M.A., et al. (2011) Regulation of Inflammation by Short Chain Fatty Acids. Nutrients, 3, 858-876.
https://doi.org/10.3390/nu3100858
|
[68]
|
Koh, A., et al. (2016) From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell, 165, 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
|
[69]
|
Arpaia, N., et al. (2013) Metabolites Produced by Commensal Bac-teria Promote Peripheral Regulatory T-Cell Generation. Nature, 504, 451-455. https://doi.org/10.1038/nature12726
|
[70]
|
Smith, P.M., et al. (2013) The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. Science, 341, 569-573. https://doi.org/10.1126/science.1241165
|
[71]
|
Chang, P.V., et al. (2014) The Microbial Metabolite Butyrate Regu-lates Intestinal Macrophage Function via Histone Deacetylase Inhibition. Proceedings of the National Academy of Sci-ences of the United States of America, 111, 2247- 2252. https://doi.org/10.1073/pnas.1322269111
|
[72]
|
Wang, Y.D., et al. (2011) The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), Negatively Regulates Hepatic Inflammatory Response through Antagonizing Nuclear Factor κ Light-Chain Enhancer of Activated B Cells (NF-κB) in Mice. Hepa-tology, 54, 1421-1432. https://doi.org/10.1002/hep.24525
|
[73]
|
Biagioli, M. and Carino, A. (2017) The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. The Journal of Immunology, 199, 718-733.
https://doi.org/10.4049/jimmunol.1700183
|
[74]
|
Melhem, H., Kaya, B. and Ayata, C.K. (2019) Metabolite-Sensing G Protein-Coupled Receptors Connect the Diet-Microbiota-Metabolites Axis to Inflammatory Bowel Disease. Cells, 8, Article No. 450.
https://doi.org/10.3390/cells8050450
|
[75]
|
Kostic, A.D., Xavier, R.J. and Gevers, D. (2014) The Microbiome in In-flammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology, 146, 1489-1499. https://doi.org/10.1053/j.gastro.2014.02.009
|
[76]
|
Manichanh, C., et al. (2012) The Gut Microbiota in IBD. Nature Reviews Gastroenterology & Hepatology, 9, 599-608.
https://doi.org/10.1038/nrgastro.2012.152
|
[77]
|
Martinez, C., et al. (2008) Unstable Composition of the Fecal Mi-crobiota in Ulcerative Colitis during Clinical Remission. American Journal of Gastroenterology, 103, 643-648. https://doi.org/10.1111/j.1572-0241.2007.01592.x
|
[78]
|
Gevers, D., et al. (2014) The Treatment-Naive Microbiome in New-Onset Crohn’s Disease. Cell Host Microbe, 15, 382-392. https://doi.org/10.1016/j.chom.2014.02.005
|
[79]
|
Ohkusa, T., et al. (2003) Induction of Experimental Ulcerative Colitis by Fusobacterium varium Isolated from Colonic Mucosa of Patients with Ulcerative Colitis. Gut, 52, 79-83. https://doi.org/10.1136/gut.52.1.79
|
[80]
|
Ohkusa, T., et al. (2009) Commensal Bacteria Can Enter Colonic Epithelial Cells and Induce Proinflammatory Cytokine Secretion: A Possible Pathogenic Mechanism of Ulcerative Colitis. Journal of Medical Microbiology, 58, 535-545.
https://doi.org/10.1099/jmm.0.005801-0
|
[81]
|
Martinez-Medina, M., et al. (2009) Molecular Diversity of Esche-richia coli in the Human Gut: New Ecological Evidence Supporting the Role of Adherent-Invasive E. coli (AIEC) in Crohn’s Disease. Inflammatory Bowel Diseases, 15, 872-882. https://doi.org/10.1002/ibd.20860
|
[82]
|
Santoru, M.L., et al. (2017) Cross Sectional Evaluation of the Gut-Microbiome Metabolome Axis in an Italian Cohort of IBD Pa-tients. Scientific Reports, 7, Article No. 9523. https://doi.org/10.1038/s41598-017-10034-5
|
[83]
|
Frank, D.N., et al. (2011) Disease Phenotype and Genotype Are Associated with Shifts in Intestinal-Associated Microbiota in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 17, 179-184. https://doi.org/10.1002/ibd.21339
|
[84]
|
Yan, J.B. and Luo, M.M. (2020) The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease. Journal of Immunology Research, 2020, Article ID: 8813558. https://doi.org/10.1155/2020/8813558
|
[85]
|
Wang, Y., et al. (2019) Induction of Intestinal Th17 Cells by Flagellins from Segmented Filamentous Bacteria. Frontiers in Immunology, 10, Article No. 2750. https://doi.org/10.3389/fimmu.2019.02750
|
[86]
|
Larmonier, C.B., et al. (2015) T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome. BioMed Research International, 2015, Article ID: 504638. https://doi.org/10.1155/2015/504638
|
[87]
|
Paramsothy, S., et al. (2017) Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn’s and Colitis, 11, 1180-1199. https://doi.org/10.1093/ecco-jcc/jjx063
|
[88]
|
Narula, N., et al. (2017) Systematic Review and Me-ta-Analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflammatory Bowel Diseases, 23, 1702-1709.
https://doi.org/10.1097/MIB.0000000000001228
|
[89]
|
Shi, Y., et al. (2016) Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLOS ONE, 11, e0157259. https://doi.org/10.1371/journal.pone.0157259
|
[90]
|
Zhang, T., et al. (2021) The Potential of Akkermansia mucini-phila in Inflammatory Bowel Disease. Applied Microbiology and Biotechnology, 105, 5785-5794. https://doi.org/10.1007/s00253-021-11453-1
|
[91]
|
He, Z., et al. (2016) Alterations of the Gut Microbiome in Chi-nese Patients with Systemic Lupus Erythematosus. Gut Pathogens, 8, Article No. 64. https://doi.org/10.1186/s13099-016-0146-9
|
[92]
|
van der Meulen, T.A., et al. (2019) Shared Gut, but Distinct Oral Microbiota Composition in Primary Sjögren’s Syndrome and Systemic Lupus Erythematosus. Journal of Autoimmunity, 97, 77-87.
https://doi.org/10.1016/j.jaut.2018.10.009
|
[93]
|
Hevia, A., et al. (2014) Intestinal Dysbiosis Associated with Sys-temic Lupus Erythematosus. mBio, 5, e01548-14.
https://doi.org/10.1128/mBio.01548-14
|
[94]
|
Rodríguez-Carrio, J., et al. (2017) Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus. Frontiers in Im-munology, 8, Article No. 23.
https://doi.org/10.3389/fimmu.2017.00023
|
[95]
|
Manfredo Vieira, S. and Hiltensperger, M. (2018) Translocation of a Gut Pathobiont Drives Autoimmunity in Mice and Humans. Science, 359, 1156-1161. https://doi.org/10.1126/science.aar7201
|
[96]
|
Liu, Y., Alookaran, J.J. and Rhoads, J.M. (2018) Probiotics in Auto-immune and Inflammatory Disorders. Nutrients, 10, Article No. 1537. https://doi.org/10.3390/nu10101537
|
[97]
|
Esmaeili, S.A., et al. (2017) Tolerogenic Probiotics: Potential Immuno-regulators in Systemic Lupus Erythematosus. Jour- nal of Cellular Physiology, 232, 1994-2007. https://doi.org/10.1002/jcp.25748
|
[98]
|
Yeh, Y.L., et al. (2021) Heat-Killed Lactobacillus reuteri GMNL-263 In-hibits Systemic Lupus Erythematosus-Induced Cardiomyopathy in NZB/W F1 Mice. Probiotics and Antimicrobial Pro-teins, 13, 51-59.
https://doi.org/10.1007/s12602-020-09668-1
|
[99]
|
Khorasani, S. and Mahmoudi, M. (2019) Amelioration of Regu-latory T Cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in Pristane-Induced Lupus Mice Model. Jour-nal of Cellular Physiology, 234, 9778-9786.
https://doi.org/10.1002/jcp.27663
|
[100]
|
de la Visitación, N., Robles-Vera, I. and Toral, M. (2020) Lactobacillus fermentum CECT5716 Prevents Renal Damage in the NZBWF1 Mouse Model of Systemic Lupus Erythematosus. Food & Function, 11, 5266-5274.
https://doi.org/10.1039/D0FO00578A
|
[101]
|
Toral, M., et al. (2019) Lactobacillus fermentum CECT5716: A Novel Alternative for the Prevention of Vascular Disorders in a Mouse Model of Systemic Lupus Erythematosus. The FASEB Journal, 33, 10005-10018.
https://doi.org/10.1096/fj.201900545RR
|
[102]
|
Liu, R., et al. (2017) Gut Microbiome and Serum Metabolome Alter-ations in Obesity and after Weight-Loss Intervention. Nature Medicine, 23, 859-868. https://doi.org/10.1038/nm.4358
|
[103]
|
Gurung, M., et al. (2020) Role of Gut Microbiota in Type 2 Diabetes Patho-physiology. EBioMedicine, 51, Article ID: 102590. https://doi.org/10.1016/j.ebiom.2019.11.051
|
[104]
|
Kudelka, M.R., et al. (2020) Intestinal Epithelial Glycosylation in Homeostasis and Gut Microbiota Interactions in IBD. Nature Reviews Gastroenterology & Hepatology, 17, 597-617. https://doi.org/10.1038/s41575-020-0331-7
|
[105]
|
Gupta, A. and Osadchiy, V. (2020) Brain-Gut-Microbiome Interactions in Obesity and Food Addiction. Nature Reviews Gastroen-terology & Hepatology, 17, 655-672. https://doi.org/10.1038/s41575-020-0341-5
|
[106]
|
Quigley, E.M.M. (2017) Gut Microbiome as a Clinical Tool in Gastrointestinal Disease Management: Are We There Yet? Nature Reviews Gas-troenterology & Hepatology, 14, 315-320. https://doi.org/10.1038/nrgastro.2017.29
|
[107]
|
Wu, G.D., et al. (2016) Comparative Metabolomics in Vegans and Omnivores Reveal Constraints on Diet-Dependent Gut Microbiota Metabolite Production. Gut, 65, 63-72. https://doi.org/10.1136/gutjnl-2014-308209
|
[108]
|
Devkota, S. (2016) MICROBIOME. Prescription Drugs Obscure Microbiome Analyses. Science, 351, 452-453.
https://doi.org/10.1126/science.aaf1353
|